OncoMatch

OncoMatch/Clinical Trials/NCT06057935

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Is NCT06057935 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pemetrexed and Cisplatin for malignant peritoneal mesothelioma.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06057935Data as of May 2026

Treatment: Pemetrexed · Cisplatin · Carboplatin — The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Check if I qualify

Extracted eligibility criteria

Cancer type

Mesothelioma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: intraperitoneal chemotherapy

Cannot have received: systemic chemotherapy

Cannot have received: platinum-based chemotherapy

Lab requirements

Blood counts

ANC ≥ 1,500/µl; Platelets > 75,000/µl

Kidney function

creatinine < 1.5× ULN or calculated creatinine clearance of ≥50 ml/min

Liver function

bilirubin < 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL)

Hematology: ANC ≥ 1,500/µl. Platelets > 75,000/µl. Adequate renal function: creatinine < 1.5× ULN or calculated creatinine clearance of ≥50 ml/min. Adequate hepatic function: bilirubin < 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Chicago (Data Collection Only) · Chicago, Illinois
  • University of Michigan (Data Collection Only) · Ann Arbor, Michigan
  • Washington University (Data Collection Only) · St Louis, Missouri
  • University of Nebraska (Data collection only) · Omaha, Nebraska
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify